# Efficacy and Safety of the LovenoxTM (Enoxaparin) Versus HeparinTM Gynecologic Oncology Patients

> **NCT01356329** · PHASE3 · SUSPENDED · sponsor: **National Guard Health Affairs** · enrollment: 150 (estimated)

## Conditions studied

- Malignant Female Reproductive System Neoplasm

## Interventions

- **DRUG:** Enoxaparin, Heparin

## Key facts

- **NCT ID:** NCT01356329
- **Lead sponsor:** National Guard Health Affairs
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2009-10
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 150 (ESTIMATED)
- **Why stopped:** Difficulty in enrolling patients
- **Last updated:** 2016-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01356329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01356329, "Efficacy and Safety of the LovenoxTM (Enoxaparin) Versus HeparinTM Gynecologic Oncology Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01356329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*